📰 Lars Iversen News
Lars Iversen News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Lars Iversen. Real-time updates on events, politics, business and more.
October 11, 2023
MC2-32 (RGRN-305) a first in class, oral therapy targeting multiple pathways involved in Hidradenitis Suppurativa (HS) achieves highly positive data in...
October 11, 2023
MC2-32 (RGRN-305) a first in class, oral therapy targeting multiple pathways involved in Hidradenitis Suppurativa (HS) achieves highly positive data in randomized, double-blinded, placebo-controlled trial in 15 patients:Primary endpoint, HiSCR50
September 26, 2023
MC2 Therapeutics Acquires Option to Phase 2 Oral Drug Candidate for Hidradenitis Suppurativa and Other IndicationsOption to exclusively license the rights to develop, manufacture and commercialize “RGRN-305” for all human indications, incl. oral treatment of Hidradenitis Suppurativa (“HS”)RGR...
September 25, 2023
Option to exclusively license the rights to develop, manufacture and commercialize “RGRN-305” for all human indications, incl. oral treatment of Hidradenitis Suppurativa (“HS”)RGRN-305 is a new chemical entity having a novel mode of action targeting HSClinical data from a double-blinded placebo-controlled Ph2a trial...
September 25, 2023
MC2 Therapeutics has acquired the exclusive licensing rights for Regranion’s RGRN-305, a new treatment for hidradenitis suppurativa (HS).
September 16, 2022
Psoriasis is associated with a range of comorbidities. But while these comorbidities are well-known, many still go overlooked and are underdiagnosed.
June 9, 2022
/PRNewswire/ -- MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at...
June 9, 2022
Copenhagen (ots/PRNewswire) - MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at Aarhus University Hospital and at Aarhus University, its new full-time Chief Medical Officer (CMO) as of October 1st, 2022.Professor Lars Iversen will be a key member of the Ex...
May 24, 2022
Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, announced today the commercial launch in Denmark of Wynzora® cream (50 µg/g calcipotriol and 0.5 mg/g betamethasone as dipropionate), developed for the topical treatment of mild to moderate plaque psoriasis in adults including ...